Introduction to the main mechanism of action and indications of giritinib

Gilitinib is an oral small molecule targeted drug that is a tyrosine kinase inhibitor. It mainly exerts anti-tumor effects by inhibiting the FLT3 (FMS-like tyrosine kinase3) mutation signaling pathway. FLT3 is one of the common types of pathogenic gene mutations in acute myeloid leukemia (AML), especially FLT3-ITD and FLT3-TKD mutations, which can cause abnormal proliferation of leukemia cells. Giritinib precisely targets these mutations and blocks cell signaling, thereby inhibiting the growth of leukemia cells and inducing apoptosis.

The main indication of giritinib is the treatment of adult patients with FLT3 mutant acute myeloid leukemia that has relapsed or been refractory to treatment. For this type of patients, traditional chemotherapy has limited efficacy, high recurrence rate, and short survival period. The emergence of giritinib provides new treatment options for these patients. Its monotherapy has shown high response rates and prolonged progression-free survival in multiple clinical trials, especially when other treatment options have failed.

In addition to its efficacy against FLT3mutated AML, giritinib also exhibits certain multi-target inhibitory effects, such as AXL and other tyrosine kinase activities. This broad-spectrum inhibitory ability also shows certain therapeutic potential in some patients with non-FLT3 mutations. However, at present, its approved indications are still mainly focused on FLT3 mutation-positive people, and it is recommended to confirm whether the patient carries the mutation through molecular testing before use.

In summary, giritinib, as a precisely targeted drug, is of great significance in the treatment of FLT3 mutation-related acute myeloid leukemia. Its characteristics of oral use, clear efficacy, and controllable side effects make it an important treatment option for patients with refractory or relapsed AML. In the future, with the accumulation of more clinical data, giritinib is expected to be applied to a wider range of hematological tumors.

Reference materials:https://www.xospata.com/